JP2004535196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004535196A5 JP2004535196A5 JP2003507279A JP2003507279A JP2004535196A5 JP 2004535196 A5 JP2004535196 A5 JP 2004535196A5 JP 2003507279 A JP2003507279 A JP 2003507279A JP 2003507279 A JP2003507279 A JP 2003507279A JP 2004535196 A5 JP2004535196 A5 JP 2004535196A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- group
- sequence
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims 26
- 108091033319 polynucleotide Proteins 0.000 claims 22
- 102000040430 polynucleotide Human genes 0.000 claims 22
- 239000002157 polynucleotide Substances 0.000 claims 22
- 239000002773 nucleotide Substances 0.000 claims 18
- 125000003729 nucleotide group Chemical group 0.000 claims 18
- 238000000034 method Methods 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 12
- 102220202377 rs1057522318 Human genes 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 230000004071 biological effect Effects 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 7
- 108091026890 Coding region Proteins 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 102220242717 rs1553780837 Human genes 0.000 claims 6
- 102220329691 rs892807467 Human genes 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000009510 drug design Methods 0.000 claims 2
- 238000003205 genotyping method Methods 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010007275 Carcinoid tumour Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 108010067902 Peptide Library Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 230000004041 dendritic cell maturation Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 238000013537 high throughput screening Methods 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 108091027963 non-coding RNA Proteins 0.000 claims 1
- 102000042567 non-coding RNA Human genes 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0105919A FR2824333B1 (fr) | 2001-05-03 | 2001-05-03 | Nouveaux polynucleotides et polypeptides de l'ifn alpha 5 |
| PCT/EP2002/005458 WO2003000896A2 (en) | 2001-05-03 | 2002-05-02 | POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004535196A JP2004535196A (ja) | 2004-11-25 |
| JP2004535196A5 true JP2004535196A5 (enExample) | 2005-09-15 |
Family
ID=8862939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003507279A Pending JP2004535196A (ja) | 2001-05-03 | 2002-05-02 | ＩＦＮα−５遺伝子のポリヌクレオチド及びポリペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7358333B2 (enExample) |
| EP (1) | EP1383895A2 (enExample) |
| JP (1) | JP2004535196A (enExample) |
| AU (1) | AU2002319176A1 (enExample) |
| FR (1) | FR2824333B1 (enExample) |
| WO (1) | WO2003000896A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| FR2822845B1 (fr) * | 2001-03-30 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
| WO2011017160A1 (en) * | 2009-07-28 | 2011-02-10 | Pestka Biomedical Laboratories, Inc. | Mutant human interferon proteins and genes |
| LT6164B (lt) | 2013-10-15 | 2015-06-25 | Uab Biotechnologinės Farmacijos Centras "Biotechpharma" | Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas |
| US11208485B2 (en) | 2018-10-11 | 2021-12-28 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| WO2020076970A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
| TW202506736A (zh) | 2018-10-11 | 2025-02-16 | 美商因荷布瑞克斯生物科學公司 | 5t4單域抗體及其治療性組合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI86558C (fi) | 1980-01-08 | 1992-09-10 | Biogen Inc | Dna- sekvenser, rekombinant-dna- molekyler och foerfaranden foer framstaellning av humant interferon av -typ och val av dna-sekvensen. |
| US4973479A (en) | 1982-01-15 | 1990-11-27 | Cetus Corporation | Interferon-α61 |
| WO1983002461A1 (en) * | 1982-01-19 | 1983-07-21 | Cetus Corp | Multiclass hybrid interferons |
| US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| JPS6156199A (ja) * | 1984-08-27 | 1986-03-20 | Shionogi & Co Ltd | 新規ヒトインタ−フエロンα類 |
| US5705363A (en) * | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
| EP0941366A2 (en) * | 1996-11-06 | 1999-09-15 | Whitehead Institute For Biomedical Research | Biallelic markers |
| US6299869B1 (en) * | 1997-12-08 | 2001-10-09 | Genentech, Inc. | Human interferon-epsilon: a type I interferon |
| ES2138565B1 (es) * | 1998-05-13 | 2000-08-16 | Inst Cientifico Tecnol Navarra | Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es. |
| AU4845699A (en) * | 1998-07-28 | 2000-02-21 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Interferon alpha hybrids |
| AU8001300A (en) * | 1999-10-07 | 2001-05-10 | Maxygen, Inc. | Ifn-alpha homologues |
-
2001
- 2001-05-03 FR FR0105919A patent/FR2824333B1/fr not_active Expired - Fee Related
-
2002
- 2002-05-02 JP JP2003507279A patent/JP2004535196A/ja active Pending
- 2002-05-02 AU AU2002319176A patent/AU2002319176A1/en not_active Abandoned
- 2002-05-02 EP EP02748710A patent/EP1383895A2/en not_active Withdrawn
- 2002-05-02 WO PCT/EP2002/005458 patent/WO2003000896A2/en not_active Ceased
-
2003
- 2003-11-03 US US10/698,402 patent/US7358333B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaiser et al. | Differential cytokine responses following Marek's disease virus infection of chickens differing in resistance to Marek's disease | |
| Crow et al. | Microarray analysis of interferon-regulated genes in SLE | |
| Piaszyk-Borychowska et al. | Signal integration of IFN-I and IFN-II with TLR4 involves sequential recruitment of STAT1-complexes and NFκB to enhance pro-inflammatory transcription | |
| Zingoni et al. | Cutting edge: the chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells | |
| Kiyoi et al. | Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia | |
| Fletcher et al. | Transcriptomic analysis of the woodchuck model of chronic hepatitis B | |
| Rappa et al. | Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity | |
| JP2004533240A5 (enExample) | ||
| Blum et al. | Three human homologs of a murine gene encoding an inhibitor of stem cell proliferation | |
| Kouno et al. | Up-regulation of CC chemokine, CCL3L1, and receptors, CCR3, CCR5 in human glioblastoma that promotes cell growth | |
| Wang et al. | Signal transducer and activator of transcription 4 in liver diseases | |
| JP2005520834A5 (enExample) | ||
| RU2003133982A (ru) | Новые полинуклеотиды и полипептиды гена ifn альфа-17 | |
| JP2004535196A5 (enExample) | ||
| Haugland et al. | Differential expression profiles and gene structure of two tumor necrosis factor-α variants in Atlantic salmon (Salmo salar L.) | |
| JP2005500029A5 (enExample) | ||
| Freaney et al. | High-density nucleosome occupancy map of human chromosome 9p21–22 reveals chromatin organization of the type I interferon gene cluster | |
| Mir et al. | Introduction to Cytokine and Chemokine Networks | |
| Zhang et al. | Possible modulation by male sex hormone of Th1/Th2 function in protection against Plasmodium chabaudi chabaudi AS infection in mice | |
| Xiang et al. | Liver transcriptome analysis of the Sparus macrocephlus in response to Vibrio parahaemolyticus infection | |
| Certa et al. | Expression modes of interferon-α inducible genes in sensitive and resistant human melanoma cells stimulated with regular and pegylated interferon-α | |
| JP2005500029A (ja) | ＩＦＮα−７遺伝子の新規ポリヌクレオチド及びポリペプチド | |
| Udar et al. | NS22: a highly polymorphic complex microsatellite marker within the ATM gene | |
| Yeh et al. | Sequence analysis, characterization and mRNA distribution of channel catfish (Ictalurus punctatus Rafinesque, 1818) chemokine (CXC motif) receptor 4 (CXCR4) cDNA | |
| Zeng et al. | Recent perspectives of ependymomas (childhood brain tumors). |